Last 14 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | 0.05 | — | — | — | — | 3.89 | 2.81 | 2.66 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.14 | 0.07 | 0.00 | 0.02 | 0.15 | 0.06 | 0.17 | 0.19 | 0.28 | 0.49 | 0.78 | — | — | — | — |
| — | +11.4% | -99.8% | -88.4% | -44.4% | -87.7% | -78.6% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.04 | 0.00 | 0.02 | 0.30 | 0.09 | 0.26 | 0.26 | 0.44 | 0.80 | 1.50 | — | — | — | — |
| — | -50.6% | -99.9% | -92.5% | -32.3% | -89.3% | -82.5% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | 0.00 | — | — | — | 0.65 | — | 1.11 | — | 18.89 | — | — | — | — |
| — | — | -99.8% | — | — | — | -96.6% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 2.17 | — | 1.43 | 2.56 | 1.09 | — | — | — | — |
| — | — | — | — | — | — | +98.6% | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | -1.16 | — | — | 2.64 | — | 1.26 | 2.58 | 1.12 | — | — | — | — |
| — | — | — | — | — | — | +136.2% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.3% | 36.0% | 34.6% | 27.9% | 25.2% | 29.4% | 32.6% | 50.5% | 56.3% | 56.0% | 48.9% | 45.9% | 45.9% | 40.3% | 47.0% |
| — | +22.7% | +6.2% | -44.8% | -55.3% | -47.6% | -33.3% | +10.1% | +22.7% | +38.8% | +3.9% | — | — | — | — | |
| Operating Margin | -16.3% | -6.8% | -25.4% | -61.9% | -13.5% | -26.6% | 0.8% | -63.6% | 11.2% | 16.9% | 39.4% | 33.7% | 33.7% | 29.4% | 33.9% |
| — | +74.5% | -3245.4% | +2.6% | -221.0% | -257.0% | -98.0% | -288.7% | -66.9% | -42.4% | +16.5% | — | — | — | — | |
| Net Margin | -20.6% | -4.4% | -35.9% | 43.1% | -101.7% | -39.4% | -3.9% | -65.7% | 7.2% | 17.6% | 29.4% | 24.6% | 24.6% | 22.7% | 26.7% |
| — | +88.7% | -826.4% | +165.7% | -1521.1% | -323.5% | -113.2% | -366.8% | -70.9% | -22.5% | +10.3% | — | — | — | — |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.2% | -0.7% | -6.5% | 12.1% | -39.5% | -12.6% | -1.5% | -19.5% | 2.9% | 7.6% | 20.0% | 19.7% | 25.3% | 34.2% | 39.3% |
| — | +94.5% | -326.7% | +162.2% | -1470.9% | -265.2% | -107.6% | -198.5% | -88.6% | -77.8% | -49.1% | — | — | — | — | |
| ROA | -5.4% | -0.5% | -4.4% | 7.5% | -25.5% | -8.8% | -1.1% | -16.0% | 2.4% | 6.1% | 14.9% | 13.6% | 16.9% | 16.4% | 13.5% |
| — | +94.1% | -301.3% | +146.6% | -1142.3% | -245.1% | -107.4% | -217.6% | -85.6% | -63.1% | +9.9% | — | — | — | — | |
| ROIC | -7.8% | -1.9% | -8.8% | -19.5% | -4.1% | -7.1% | 0.3% | -15.8% | 3.8% | 8.3% | 46.6% | 35.9% | 38.9% | 41.0% | 59.2% |
| — | +73.7% | -3360.8% | -22.9% | -207.0% | -185.4% | -99.4% | -144.1% | -90.2% | -79.8% | -21.3% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.14 | 0.18 | 0.24 | 0.14 | 0.09 | 0.08 | 0.07 | 0.07 | 0.05 | 0.13 | 0.15 | 0.20 | 0.27 |
| — | +18.9% | +61.9% | +107.3% | +237.5% | +88.6% | +59.8% | -33.4% | -50.4% | -63.9% | -80.0% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | 10.02 | — | 1.47 | 1.03 | 0.28 | 0.49 | 0.47 | 0.50 | 0.52 |
| — | — | — | — | — | — | +3485.7% | — | +212.1% | +107.6% | -46.1% | — | — | — | — | |
| Current Ratio | 4.07 | 4.07 | 2.78 | 2.54 | 1.63 | 2.68 | 2.26 | 3.17 | 5.06 | 4.50 | 3.73 | 2.91 | 2.29 | 2.24 | 1.19 |
| — | +52.0% | +22.9% | -19.8% | -67.9% | -40.6% | -39.4% | +8.9% | +121.0% | +100.8% | +212.3% | — | — | — | — | |
| Quick Ratio | 3.90 | 3.90 | 2.60 | 2.46 | 1.44 | 2.43 | 2.14 | 3.00 | 4.73 | 4.28 | 3.43 | 2.67 | 1.75 | 1.76 | 0.75 |
| — | +60.4% | +21.6% | -18.1% | -69.5% | -43.2% | -37.7% | +12.3% | +169.7% | +142.9% | +356.2% | — | — | — | — | |
| Interest Coverage | -14.83 | -2.75 | -24.51 | 31.49 | -90.03 | -49.35 | 4.47 | -152.12 | 38.45 | 76.00 | 205.15 | 82.61 | 82.61 | 75.67 | 58.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UPC stock.
Universe Pharmaceuticals Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Universe Pharmaceuticals Inc.'s current operating margin is -16.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Universe Pharmaceuticals Inc.'s business trajectory between earnings reports.